Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Shuyao Liang"'
Autor:
Tingting Qiu, Michal Pochopien, Shuyao Liang, Gauri Saal, Ewelina Paterak, Justyna Janik, Mondher Toumi
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Gene therapies (GTs) are considered to be a paradigm-shifting class of treatments with the potential to treat previously incurable diseases or those with significant unmet treatment needs. However, considerable challenges remain in their health techn
Externí odkaz:
https://doaj.org/article/b57a89d406e24497bed23c955ee85b90
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Some advanced therapy medicinal products (ATMPs) hold great promises for life-threatening diseases with high unmet needs. However, ATMPs are also associated with significant challenges in market access, which necessitates the joint efforts between al
Externí odkaz:
https://doaj.org/article/3953a47776f74b8ea9eba7e8b0c68ba7
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background and objective: Although the treatment of chronic hepatitis C (CHC) has significantly evolved with the introduction of direct-acting antivirals, the treatment uptake rates have been low especially among marginalized groups in the UK, such a
Externí odkaz:
https://doaj.org/article/afccf73769e5442bbe5e7ffed50faa3f
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Purpose A international registry analysis led by Mehra et al. to investigate the use of hydroxychloroquine (HCQ) and chloroquine (CQ) with or without a macrolide in 96,032 hospitalised COVID-19 patients were published on Lancet, which has raised cons
Externí odkaz:
https://doaj.org/article/38a0bd7237bf4242b571023fc31c55b4
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background and Objective: China has managed to control the coronavirus disease (COVID-19) with confinement measurements and treatment strategies, while other countries are struggling to contain the spread. This study discusses the guidelines related
Externí odkaz:
https://doaj.org/article/f179b6b7f219460eb9a4daec1c3441c6
Autor:
Tingting, Qiu, Michał, Pochopień, Eve, Hanna, Shuyao, Liang, Yitong, Wang, Ru, Han, Mondher, Toumi, Samuel, Aballéa
Publikováno v:
Regenerative Medicine. 17:119-139
Aim: Regenerative medicines (RMs) are expected to transform the treatment paradigm of rare, life-threatening diseases, while substantial challenges impede its market access. This study aimed to present these challenges. Materials & methods: Publicati
Publikováno v:
Regenerative medicine. 16(8)
Aim: Partnerships have been leveraged to advance the regenerative medicines (RMs) development. This study analyzed the evolution of partnership landscape for regenerative medicines (RMs). Methods: Partnership agreements publicly announced from Januar
Publikováno v:
Human gene therapy. 33(1-2)
China, the first country worldwide to approve a gene therapy in 2003, almost lost the advantage for a head start in cell and gene therapy (CGT) development due to a lack of clear and strict regulatory frameworks. The rapid advancements of CGTs' devel
Publikováno v:
Drug Discovery Today
Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shi
Publikováno v:
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background and objective: Although the treatment of chronic hepatitis C (CHC) has significantly evolved with the introduction of direct-acting antivirals, the treatment uptake rates have been low especially among marginalized groups in the UK, such a